# RAG System Evaluation Report

**Total Queries:** 50
**Agent Execution Time:** 1922.58 seconds

## Retrieval Metrics
- **Hit Rate@5:** 0.24
- **Mean Reciprocal Rank (MRR):** 0.19
- **nDCG@5:** 0.17

## Query Breakdown
### q_synth_1: What is the diagnostic yield of limited BRCA1/2 analysis compared to multigene panel testing for pathogenic BRCA1/2 mutations in patients at risk for hereditary breast cancer?

**Expected ID:** `62b91b8f` | **Hit@5:** 0 | **MRR:** 0.00

**Execution Path:** `route_recency ➔ retrieve ➔ grade_failed ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** 13a5a4ee, PMID_41875782, PMID_42462279, PMID_42458138, NCT03211611, PMID_42464142, NCT07197723, NCT04499534, 9038ce43, PMID_41693691, ed36b174, NCT03286842, db213d0b, 83d45c9a, 41962de5, 5502812c, PMID_42224954, db8c3721, 3b86bd00, 6f97e02a, 5a660ddc, 833066f5, a6fafd7b, e3cb4218, NCT04367675, e41923b8, PMID_41520277, PMID_42437126

#### Generated Answer

> Here are the relevant claims or metrics related to BRCA1/2 extracted from the provided context:

* An individual with a known deleterious BRCA1/2 mutation in a close family member who does not undergo gene testing should be followed according to the same screening/management guidelines as a carrier of a BRCA1/2 mutation [NCCN 13a5a4ee]
* Rare germline BRCA1/2 variants were identified in 17 of 367 patients (4.6%) with pediatric, adolescent, and young adult (AYA) patients with central nervous system tumors [PubMed PMID_42458138]
* Pathogenic or likely pathogenic BRCA1/2 variants were identified in 5 patients (1.4% of the overall cohort) among the 367 patients [PubMed PMID_42458138]
* Variants of uncertain significance (VUSs) were identified in 12 patients (3.3%) with pediatric, adolescent, and young adult (AYA) patients with central nervous system tumors [PubMed PMID_42458138]
* Patients undergoing PGT-M, including BRCA carriers, experience greater cumulative IVF cycle burden, but the per cycle and per transfer probability of achieving a live birth was similar across indications [PubMed PMID_42462279]
* The prevalence of BRCA1/2 mutations across different cancer types was 14.35% among Vietnamese patients diagnosed with breast, ovarian, prostate, or pancreatic cancer [PubMed PMID_42464142]

Note that the Source ID bracket is appended to each extracted claim or metric as requested.

---

### q_synth_2: What are the characteristics of Li-Fraumeni syndrome, specifically the prevalence and diversity of constitutional TP53 gene mutations among affected families?

**Expected ID:** `17d4523d` | **Hit@5:** 0 | **MRR:** 0.10

**Execution Path:** `route_recency ➔ retrieve ➔ grade_failed ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** 8f94e72f, PMID_42297232, 91a627de, 7d408bd4, 4eddeff9, NCT04976439, f42b2268, PMID_42107262, 81d3e9e7, 17d4523d, NCT07419893, dbc35d50, c368ec89, NCT07535840, d1593f2e, 66ecb52d, PMID_42163716, 02626e7b, df2dfbb8, PMID_42320297, 6656ed38, 78aee744, PMID_42320583, PMID_42361739, NCT05631886, NCT07511062, PMID_42037246, PMID_42367244

#### Generated Answer

> Here are the extracted claims or metrics related to TP53 gene mutations:

* Li-Fraumeni syndrome (LFS) is a rare hereditary cancer syndrome associated with germline TP53 gene mutations [NCCN 8f94e72f].
* Germline TP53 gene mutations have been estimated to be involved in only about 1% of hereditary breast cancer cases [NCCN 8f94e72f].
* TP53, the tumor suppressor gene, is located on chromosome 17 [99-101].
* Germline mutations in the TP53 gene have been [PubMed PMID_42297232].
* Loss of TP53 function is associated with a marked reduction of EIF5A and hypusine level [PubMed PMID_42297232].
* Restoration of wild-type TP53 in cells supports hypusination-dependent translation of proteins involved in cell growth and renders them susceptible to DHPS inhibition [PubMed PMID_42297232].

Please note that these are the specific claims or metrics related to TP53 gene mutations extracted from the provided context blocks.

---

### q_synth_3: What is the recommended timing for performing breast self-examination (BSE) for premenopausal women?

**Expected ID:** `93d87b05` | **Hit@5:** 0 | **MRR:** 0.08

**Execution Path:** `route_conceptual ➔ retrieve ➔ grade_insufficient ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** PMID_42436446, PMID_41546558, NCT06371508, PMID_42392264, NCT07692464, NCT01271673, NCT05960643, NCT07348744, PMID_42450991, e3f0b71f, 32101cad, f348e333, 93d87b05, 0ca27aa5, c093a2dd, 59b73b57, e7a138c0, df3c1b7b, f81b01d4, 382d6c7d, 471a582e, df07e7df, PMID_42446397, PMID_42173439, 2f2f3eaa, PMID_42386721, PMID_42371320, dd9edc80

#### Generated Answer

> Based on the provided context, here are some claims and metrics related to breast self-examination:

1. Breast cancer knowledge increased significantly in all participants from pretest to posttest (p < 0.001) [PubMed PMID_42436446]
2. Regular BSE practice increased from 0% at baseline to 60% at follow-up across the cohort, with a significantly greater increase in the hands-on training group compared with the theoretical-only group (75% vs. 45%, p = 0.038) [PubMed PMID_42436446]
3. Self-efficacy emerged as the strongest predictor of BSE practice (OR= 1.83, 95% CI:1.69-1.98, P = 0.053) [PubMed PMID_42392264]
4. Perceived susceptibility was also significantly associated with BSE practice (OR= 1.71, 95% CI:1.56-1.91, P = 0.008) [PubMed PMID_42392264]
5. Health-motivation demonstrated a positive association with BSE practice (OR= 1.29, 95% CI:1.08-1.54, P = 0.005) [PubMed PMID_42392264]

These findings suggest that breast self-examination is an important method for promoting early detection of breast cancer and that increasing knowledge, self-efficacy, and perceived susceptibility can lead to increased BSE practice.

---

### q_synth_4: What is the recommended surveillance strategy for germline TP53 mutation carriers with Li-Fraumeni syndrome?

**Expected ID:** `81d3e9e7` | **Hit@5:** 1 | **MRR:** 0.20

**Execution Path:** `route_conceptual ➔ retrieve ➔ grade_insufficient ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** 4eddeff9, NCT05778149, 91a627de, 8f94e72f, 81d3e9e7, NCT07535840, dbc35d50, 7d408bd4, c368ec89, f42b2268, d1593f2e, 17d4523d, NCT06413992, ba24e8d6, PMID_42163716, 66ecb52d, NCT07419893, 6656ed38, PMID_42376199, NCT07511062, df2dfbb8, 02626e7b, PMID_42466845, PMID_41972336, PMID_41589893, PMID_42037246, PMID_41593906, PMID_41666291

#### Generated Answer

> Based on the provided context blocks, here are the claims and metrics related to TP53 mutations:

* The lifetime risk of breast cancer has been estimated at about 1/10th of 1% (1 in 1,000) among individuals with Li-Fraumeni syndrome [NCCN 8f94e72f].
* Germline TP53 gene mutations have been found to be involved in only about 1% of hereditary breast cancer cases [NCCN 96].
* The tumor suppressor gene TP53 is located on chromosome 17 and has been called the 'guardian of the genome' [NCCN 99-101].
* Germline mutations in the TP53 gene have been associated with Li-Fraumeni syndrome, a rare hereditary cancer syndrome [NCCN 81d3e9e7].
* The prevalence of constitutional mutations in the p53 gene among Li-Fraumeni families has been estimated to be around 21% [NCCN 104].
* The TP53 mutational spectrum and frequency of CHEK2*1100delC in Li-Fraumeni-like kindreds have been reported [Siddiqui R, Onel K, Facio F, et al. The TP53 mutational spectrum and frequency of CHEK2*1100delC in Li-Fraumeni-like kindreds. Fam Cancer 2005;4:177-181. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15951970].
* Risks of first and subsequent cancers among TP53 mutation carriers have been reported [Mai PL, Best AF, Peters JA, et al. Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute LiFraumeni syndrome cohort. Cancer 2016;122:3673-3681. Available at: https://www.ncbi.nlm.nih.gov/pubmed/27496084].

Note that these claims and metrics are related to the context blocks provided, and may not represent the entire scope of knowledge on TP53 mutations.

---

### q_synth_5: What are the reported cases of Peutz-Jeghers syndrome associated with breast cancer, ovarian sex cord tumor with annular tubules, and adenoma malignum?

**Expected ID:** `c1918410` | **Hit@5:** 0 | **MRR:** 0.17

**Execution Path:** `route_conceptual ➔ retrieve ➔ grade_insufficient ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** NCT06242457, NCT03806075, NCT06001476, PMID_42335429, NCT00811590, c1918410, debd66f8, PMID_42410002, NCT03781050, PMID_42399437, PMID_42423930, PMID_42439066, eb7b875b, 7e6908ae, 227a15bf, PMID_42419310, b28145a7, b8c62b1f, ce75bad4, 3aa8ab22, e637396b, PMID_42419308, bf7df0a5, dff7d8e5, 005a4517, 8bb5f2d3, 5955a477, PMID_41910454

#### Generated Answer

> Based on the provided context, here are some claims and metrics related to Peutz-Jeghers syndrome:

* The mutation of STK11 has been recognized as the major cause of Peutz-Jeghers syndrome (PJS) [ClinicalTrials.gov NCT03806075]
* The investigators aimed to confirm the mutation rate of genes associated with gastrointestinal malignancies, including STK11, APC, PMS1, et al. in patients with PJS [ClinicalTrials.gov NCT03806075]
* Cold snare polypectomy for removing 5-9mm small intestinal polyps has been evaluated for feasibility and safety in patients with Peutz-Jeghers Syndrome (PJS) [ClinicalTrials.gov NCT06001476]
* Artificial intelligence-integrated nanotherapeutics have been proposed as a potential treatment approach for rare PJS hamartoma-induced obstructions [PubMed PMID_42335429]
* Everolimus has been investigated as a potential treatment option to diminish large gastrointestinal polyps in patients with Peutz-Jeghers Syndrome [ClinicalTrials.gov NCT00811590]

These are just some of the claims and metrics related to Peutz-Jeghers syndrome that can be extracted from the provided context.

---

### q_synth_6: What is the long-term risk of breast cancer associated with lobular neoplasia?

**Expected ID:** `71cae268` | **Hit@5:** 1 | **MRR:** 1.00

**Execution Path:** `route_recency ➔ retrieve ➔ grade_failed ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_fail ➔ generate ➔ validate_fail`

**Retrieved Sources:** 71cae268, e36481d3, PMID_42176390, NCT07613151, PMID_42014495, 7a58d5d0, 3469e7f2, PMID_42011085, ce75bad4, PMID_42220308, 1b4ff988, PMID_41704167, PMID_41918273, NCT05960201, b28145a7, NCT07313033, NCT06666439, b0545db9, eb7b875b, 67af1f9f, PMID_42081023, PMID_42135547, 65504cd1, c89916bc, 3aa8ab22, 5955a477, 7d408bd4, NCT06744101

#### Generated Answer

> Limited family structure and BRCA gene mutation status in single cases of breast cancer was studied, revealing that the majority of lobular neoplasms occurred in women with no known family history [NCCN].

The long-term risk of breast cancer associated with lobular neoplasia was found to be significant, with a cumulative incidence of 25% at 15 years and 55% at 20 years [Bodian CA, Perzin KH, Lattes R. Lobular neoplasia. Long term risk of breast cancer and relation to other factors. Cancer 1996;78:1024-1034.].

According to the study, the risk of breast cancer is significantly increased in women with lobular neoplasia, regardless of family history [Bodian CA, Perzin KH, Lattes R. Lobular neoplasia. Long term risk of breast cancer and relation to other factors. Cancer 1996;78:1024-1034.].

A retrospective study found that women with lobular neoplasia were more likely to develop invasive lobular carcinoma (ILC) [PubMed PMID_42014495].

---

### q_synth_7: What types of cancers are included in Lynch syndrome/hereditary non-polyposis colorectal cancer?

**Expected ID:** `262ba92a` | **Hit@5:** 0 | **MRR:** 0.00

**Execution Path:** `route_recency ➔ retrieve ➔ grade_insufficient ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** NCT07360834, NCT07445828, PMID_42288229, 2ab3e079, 5636e4d7, PMID_41460162, e3ab2065, NCT07412197, PMID_42269807, c79d45a7, PMID_42419314, 45b869ce, 2d34c6c7, aed176f5, eb7b875b, PMID_42341482, PMID_42383458, 625ff878, 8ac9cf7c, 397bd923, ecc80356, PMID_42419310, NCT00341575, 3aa8ab22, PMID_42419308, 5955a477, 7d408bd4, NCT00262171

#### Generated Answer

> Based on the provided context blocks, here are some claims and metrics related to Lynch syndrome:

* Lynch syndrome is an inherited genetic predisposition that increases the risk of developing several types of cancer, particularly colon and rectal cancers (colorectal cancer), as well as cancer of the uterine lining (endometrial cancer). [ClinicalTrials.gov NCT07360834]
* The estimated lifetime risk of colorectal cancer varies by the affected gene and is approximately 54-74% in men and 30-52% in women with Lynch syndrome. [ClinicalTrials.gov NCT07445828]
* Lynch syndrome is the most common hereditary cancer syndrome. [ClinicalTrials.gov NCT07445828]
* The primary cause of Lynch syndrome is pathogenic variants in DNA mismatch repair genes. [ClinicalTrials.gov NCT07445828]
* Lynch syndrome accounts for approximately 2% to 3% of all colorectal cancer cases. [PubMed PMID_42288229]
* Individuals with Lynch syndrome have a significantly elevated cancer risk among affected family members, necessitating targeted preventive interventions. [PubMed PMID_42288229]

---

### q_synth_8: What are the histopathology, FIGO stage, and BRCA mutation status of ovarian cancers from the Gilda Radner Familial Ovarian Cancer Registry?

**Expected ID:** `227a15bf` | **Hit@5:** 0 | **MRR:** 0.00

**Execution Path:** `route_recency ➔ retrieve ➔ grade_insufficient ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_fail ➔ generate ➔ validate_fail`

**Retrieved Sources:** PMID_42377119, NCT03838406, a6fafd7b, 4a846d8b, cf59ea9b, NCT02034916, NCT02222883, e3cb4218, 5a660ddc, NCT06831747, 3404e0ab, PMID_41454916, 373661ac, 285852e3, 2fa26ed8, dbbb8e61, PMID_42116756, 767a1cf8, PMID_42235423, PMID_42259465, NCT01945775, b8a2d9ff, 3f8ded64, 8d4ac645, PMID_42155200, PMID_42189063, 914ccbf5, PMID_42247992

#### Generated Answer

> The context provided mentions several studies related to BRCA (Breast Cancer Gene). Here are the claims or metrics extracted from the context:

* The transcription factor In BRCA [PubMed PMID_42377119]
* Germline BRCA mutations denote a clinicopathologic subset of prostate cancer [NCCN a6fafd7b]
* BRCA mutations and risk of prostate cancer in Ashkenazi Jews [NCCN a6fafd7b]
* The effect of a single BRCA2 mutation on cancer in Iceland [NCCN 4a846d8b]
* Cancer risks in BRCA2 families: estimates for [NCCN 4a846d8b]
* BRCA mutations in women with inflammatory breast cancer [NCCN cf59ea9b]
* Germline BRCA1/2 mutation testing is indicated [NCCN cf59ea9b]
* Breast cancer survival of BRCA1/BRCA2 mutation carriers in a hospital-based cohort of young women [NCCN cf59ea9b]

Please note that these are the only specific claims or metrics mentioned in the context, and there may be additional information or studies related to BRCA that are not explicitly stated.

---

### q_synth_9: What is the survival rate of men with BRCA2 mutations who develop prostate cancer?

**Expected ID:** `dbbb8e61` | **Hit@5:** 0 | **MRR:** 0.12

**Execution Path:** `route_recency ➔ retrieve ➔ grade_failed ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** 5a660ddc, 56f022e5, 6f97e02a, 58138369, 549d734f, b8195f23, a8771cce, dbbb8e61, 8b1caa1c, 8dccefba, NCT04499534, NCT00899145, e3cb4218, a22210b3, 962b95df, PMID_41621779, PMID_42127212, NCT00897455, 27ee15f7, PMID_41875782, e893376a, PMID_42036279, NCT03495609, PMID_42238311, PMID_41823437, PMID_42433303, NCT04428736, PMID_42437126

#### Generated Answer

> Here are the extracted claims and metrics related to BRCA2:

* The BRCA2 gene, located on chromosome 13, is involved in repair of replication-mediated doublestrand breaks [NCCN 58138369].
* BRCA2 mutations have been associated with a 2- to 5-fold increase in risk of prostate cancer [NCCN 56f022e5].
* Prostate cancer in patients with BRCA2 mutations has been associated with a higher histologic grade [NCCN 56f022e5].
* Patients with BRCA2 mutations had significantly decreased median survival compared with non-carriers (having wild type BRCA2) patients, with a median survival of 2 years vs. 12 years; P <0.001 [NCCN 549d734f].
* In a study of patients with prostate cancer from a population-based cancer registry in Iceland (N=596), patients with BRCA2 mutations had significantly decreased median survival compared with non-carriers [NCCN 6f97e02a].
* Patients with BRCA2 mutations had more aggressive or rapidly progressive disease, and significantly decreased survival compared with patients who were BRCA1 mutation carriers or non-carriers [NCCN 56f022e5].

---

### q_synth_10: What is the family history criteria for considering genetic testing for prostate cancer patients?

**Expected ID:** `fb6e5c2f` | **Hit@5:** 0 | **MRR:** 0.00

**Execution Path:** `route_recency ➔ retrieve ➔ grade_failed ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** NCT05428319, dbbb8e61, 27ee15f7, NCT02177526, 56f022e5, PMID_42249833, PMID_41720694, 549d734f, 2fa26ed8, fdc6e3a4, cd5a8e1e, a6fafd7b, 293034b0, 54aeb8ec, PMID_42187002, 6a21b214, PMID_42304957, PMID_42252578, PMID_42359636, 2aea525d, 0a14d7c0, af1e7129, PMID_42454507, PMID_42397987, NCT01727284, NCT01743638, 1789db19, NCT03088202

#### Generated Answer

> Based on the provided context blocks, here are some claims or metrics related to prostate cancer:

* Prostate carcinoma is the second most common cancer in men [ClinicalTrials.gov NCT05428319]
* BRCA2 mutations have been associated with a 2- to 5-fold increase in risk of prostate cancer [NCCN 56f022e5]
* Patients with BRCA2 mutations had more aggressive or rapidly progressive disease, and significantly decreased survival compared with patients who were BRCA1 mutation carriers or non-carriers [NCCN 56f022e5]
* Prostate cancer in patients with BRCA2 mutations has been associated with a higher histologic grade [NCCN 56f022e5]
* Patients with prostate cancer from a population-based cancer registry in Iceland (N=596), patients with BRCA2 mutations had more aggressive or rapidly progressive disease, and significantly decreased survival compared with patients who were BRCA1 mutation carriers or non-carriers [PubMed PMID_42249833]

Note that these claims or metrics are based on the provided context blocks and may not be exhaustive.

---

### q_synth_11: What is the approximate reduction in breast cancer risk for women carrying a BRCA1/2 mutation after undergoing RRSO?

**Expected ID:** `c7827fba` | **Hit@5:** 0 | **MRR:** 0.00

**Execution Path:** `route_recency ➔ retrieve ➔ grade_failed ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** 13a5a4ee, PMID_41875782, PMID_42462279, PMID_42458138, NCT03211611, PMID_42464142, NCT07197723, NCT04499534, 9038ce43, PMID_41693691, ed36b174, NCT03286842, db213d0b, 83d45c9a, 41962de5, 5502812c, PMID_42224954, db8c3721, 3b86bd00, 6f97e02a, 5a660ddc, 833066f5, a6fafd7b, e3cb4218, NCT04367675, e41923b8, PMID_41520277, PMID_42437126

#### Generated Answer

> Based on the provided context, here are some claims or metrics related to BRCA1/2:

* An individual with a known deleterious BRCA1/2 mutation in a close family member who does not undergo gene testing should be followed according to the same screening/management guidelines as a carrier of a BRCA1/2 mutation [NCCN 13a5a4ee].
* Rare germline BRCA1/2 variants were identified in 17 of 367 patients (4.6%) with primary CNS tumors [PubMed PMID_42458138].
* Among the 195 patients undergoing IVF, number of oocytes retrieved, blastocyst yield, and embryo maturation did not differ significantly across cohorts for patients with BRCA1/2 PGT-M compared to non-BRCA PGT-M or PGT-A [PubMed PMID_42462279].
* Pathogenic BRCA1/2 variants were identified in 158 (14.35%) of Vietnamese patients diagnosed with breast, ovarian, prostate, or pancreatic cancer [PubMed PMID_42464142].

Please note that these claims and metrics are specific to the provided context and may not be generalizable to all situations or populations.

---

### q_synth_12: What is the recommended screening/management approach for an individual from a family with a known deleterious BRCA1/2 mutation who tests negative for the familial mutation?

**Expected ID:** `13a5a4ee` | **Hit@5:** 1 | **MRR:** 1.00

**Execution Path:** `route_conceptual ➔ retrieve ➔ grade_insufficient ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_fail ➔ generate ➔ validate_fail`

**Retrieved Sources:** 13a5a4ee, PMID_41875782, PMID_42462279, PMID_42458138, NCT03211611, PMID_42464142, NCT07197723, NCT04499534, 9038ce43, PMID_41693691, ed36b174, NCT03286842, db213d0b, 83d45c9a, 41962de5, 5502812c, PMID_42224954, db8c3721, 3b86bd00, 6f97e02a, 5a660ddc, 833066f5, a6fafd7b, e3cb4218, NCT04367675, e41923b8, PMID_41520277, PMID_42437126

#### Generated Answer

> Based on the provided context, I found the following claims and metrics related to BRCA1/2:

* An individual with a known deleterious BRCA1/2 mutation in a close family member who does not undergo gene testing should be followed according to the same screening/management guidelines as a carrier of a BRCA1/2 mutation [NCCN 13a5a4ee].
* Awareness and attitudes toward BRCA1/2 genetic testing among at-risk women in Egypt can be improved through structured educational awareness programs, increasing knowledge scores from 6.87 ± 2.95 to 12.74 ± 3.42 (p < 0.001) and attitude scores from 5.40 ± 2.04-9.67 ± 2.44 (p < 0.001) [PubMed PMID_41875782].
* Monoallelic BRCA1/2 variants may act as low-penetrance susceptibility factors in pediatric and young adult central nervous system tumors, rather than primary oncogenic drivers [PubMed PMID_42462279].
* The inclusion of BRCA genes in germline testing panels for pediatric and young adult central nervous system tumors is supported by these findings [PubMed PMID_42462279].
* Patients undergoing pre-implantation genetic testing for monogenic disorders (PGT-M), including those with BRCA1/2 mutations, experience greater cumulative IVF cycle burden but have a similar per-cycle probability of achieving a live birth compared to patients undergoing PGT-A or other indications [PubMed PMID_42458138].
* General practitionners play an important role in the management of women with BRCA1/2 mutation [ClinicalTrials.gov NCT03211611].
* Pathogenic BRCA1/2 variants were identified in 14.35% (158/1101) of Vietnamese patients diagnosed with breast, ovarian, prostate, or pancreatic cancer, including 57/158 ovarian, 78/158 triple-negative, 16/158 prostate, 4/158 pancreatic, and 3/158 HR-positive breast cancer [PubMed PMID_42464142].

Please note that these claims and metrics are based on the provided context blocks and may not represent the entire scope of knowledge related to BRCA1/2.

---

### q_synth_13: What are some possible genetic predispositions or family history indicators for an individual's risk of developing thyroid cancer, diffuse gastric cancer, aggressive prostate cancer, or hamartomatous polyps of the GI tract?

**Expected ID:** `3323cc1a` | **Hit@5:** 0 | **MRR:** 0.00

**Execution Path:** `route_conceptual ➔ retrieve ➔ grade_insufficient ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_fail ➔ generate ➔ validate_fail`

**Retrieved Sources:** PMID_42434118, NCT01830504, f31ad611, PMID_42153613, PMID_42430190, NCT04842994, PMID_42037453, 6492aa8b, PMID_41729615, e7af7df2, PMID_41808291, 1bfec94c, 8e7efdc5, f5cd05b2, PMID_41675769, NCT06958601, bd9b47c4, ffe636b9, 7a6ae78e, 9006cba6, NCT01690806, c4880433, NCT05624463, PMID_42189063, 16fe4400, 028c4de1, ddcbdf1c, a6fafd7b

#### Generated Answer

> Based on the provided context, I found the following claims or metrics:

1. The global age-standardized incidence rate (ASIR) of thyroid cancer among adolescents and young adults (AYAs) increased significantly from 1990-2021 [PubMed PMID_42434118].
2. The peak burden increase in thyroid cancer AYAs was observed at a low-middle Socio-demographic Index (SDI) level of 0.55 [PubMed PMID_42434118].
3. In France, approximately 7-8,000 new thyroid cancer cases are diagnosed each year [ClinicalTrials.gov NCT01830504].
4. It is estimated that 10 to 20% of patients with advanced or metastatic differentiated thyroid cancer will relapse, and 5% will become metastatic [ClinicalTrials.gov NCT01830504].
5. The standard treatment for advanced or recurrent thyroid cancer is limited to radioiodine therapy, which is estimated to be effective in only 50-70% of patients [ClinicalTrials.gov NCT01830504].
6. Aberrant activation of the phosphatidylinositol-3-kinase (PI3K)/AKT pathway is thought to play a fundamental role in thyroid tumorigenesis of follicular and poorly differentiated thyroid cancers [ClinicalTrials.gov NCT01830504].
7. SPP1 protein expression was upregulated in thyroid cancer tissues and cell lines, and enriched in TPC1-derived exosomes [PubMed PMID_42153613].
8. Exosomal SPP1 directly interacted with CD44 receptors and activated the JAK2/STAT3 signaling pathway to drive M2 polarization and promote cancer progression [PubMed PMID_42153613].
9. The frequency of PIK3CA mutations in follicular thyroid cancer was found to be 10-15%, while amplification/genomic copy gain of the PIK3CA gene was identified in 24% of follicular thyroid cancer cases [ClinicalTrials.gov NCT01830504].
10. The median overall survival rate for patients with advanced or recurrent thyroid cancer is less than 10 years, and long-term survival is estimated to be low [ClinicalTrials.gov NCT01830504].

Please note that these findings are based on the provided context blocks and may not represent a comprehensive review of all available evidence on the topic.

---

### q_synth_14: What standardized human pedigree nomenclature recommendations are available for genetic testing?

**Expected ID:** `2dba6c49` | **Hit@5:** 0 | **MRR:** 0.00

**Execution Path:** `route_recency ➔ retrieve ➔ grade_insufficient ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** NCT06926816, dee6b435, 297cda80, 972a83d6, PMID_41820818, b4ed6750, 16997f0b, 7d511538, 8c9e11cc, 78e02c2c, d1209290, NCT05159011, 4e9e4659, a6ae93d2, 78aee744, NCT04704193, NCT04856696, be27438b, 59b15f4a, PMID_41816957, PMID_41520281, PMID_42441570, PMID_41797638, PMID_41866709, e893376a, PMID_42438061, NCT07309835, PMID_42446531

#### Generated Answer

> Genetic testing can be offered to patients presenting for gynecology clinic visits [ClinicalTrials.gov NCT06926816].

The selection of appropriate candidates for genetic testing is based on personal and familial characteristics that determine the individual's prior probability of being a mutation carrier, and on the psychosocial degree of readiness of the person to receive genetic test results [NCCN 297cda80].

Genetic testing can be recommended when there is: (i) a personal or family history suggesting genetic cancer susceptibility (ii) the test can be adequately interpreted and (iii) the results will aid in the diagnosis or influence the medical or surgical management of the patient or family members at hereditary risk of cancer [NCCN 972a83d6].

Comprehensive genetic testing includes full sequencing of BRCA1 and BRCA2, as well as testing for large genomic rearrangements [NCCN b4ed6750].

---

### q_synth_15: What is the role of BRCA2 gene in DNA interstrand cross-link repair?

**Expected ID:** `5a660ddc` | **Hit@5:** 1 | **MRR:** 1.00

**Execution Path:** `route_recency ➔ retrieve ➔ grade_failed ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** 5a660ddc, 56f022e5, 6f97e02a, 58138369, 549d734f, b8195f23, a8771cce, dbbb8e61, 8b1caa1c, 8dccefba, NCT04499534, NCT00899145, e3cb4218, a22210b3, 962b95df, PMID_41621779, PMID_42127212, NCT00897455, 27ee15f7, PMID_41875782, e893376a, PMID_42036279, NCT03495609, PMID_42238311, PMID_41823437, PMID_42433303, NCT04428736, PMID_42437126

#### Generated Answer

> Here are the extracted claims or metrics related to BRCA2:

* BRCA2 mutations have been associated with a 2- to 5-fold increase in risk of prostate cancer [NCCN 56f022e5].
* Patients with BRCA2 mutations had significantly decreased median survival compared with non-carriers (having wild type BRCA2 ) patients, with 2 years vs. 12 years; P <0.001 [NCCN 549d734f].
* BRCA2 germline mutations have been found in Jewish patients with pancreatic adenocarcinoma [NCCN b8195f23].
* Deleterious BRCA2 mutations were detected in 17% of familial pancreatic cancer cases [NCCN 66e4d6a1].

Please note that these are the only specific claims or metrics related to BRCA2 extracted from the provided context.

---

### q_synth_16: What are the cancers associated with LFS, as mentioned in the guidelines?

**Expected ID:** `ff1bf449` | **Hit@5:** 0 | **MRR:** 0.10

**Execution Path:** `route_conceptual ➔ retrieve ➔ grade_insufficient ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** NCT07032922, NCT04367246, e400f40f, 8f94e72f, NCT02950987, c6d08982, cf8b4ff2, 7bf7827d, PMID_42142485, ff1bf449, 02626e7b, PMID_42284937, c434d570, PMID_42190411, PMID_42276420, edea5eda, a82b92ce, a45aff63, cca48bd4, PMID_42389043, 17941c35, f42b2268, PMID_41797681, d99fdc9f, PMID_41903381, NCT01737255, PMID_42425668, NCT02985138

#### Generated Answer

> Based on the provided context blocks, here are some key claims and metrics related to Li-Fraumeni Syndrome (LFS):

* People who have LFS are 24 times more likely to develop cancer than those who do not [No source ID].
* Lifetime malignancy risk for patients with classical LFS is between 80-90% [ClinicalTrials.gov NCT04367246].
* 21% of cancers occur by the age of 15 years in patients with classical LFS [ClinicalTrials.gov NCT04367246].
* The lifetime risk of breast cancer has been estimated at about 1/10th of 1% (1 in 1,000) for individuals with LFS [NCCN 8f94e72f].
* Germline mutations in the TP53 gene have been observed in over 50% (and in over 70% in some studies) of families meeting the classic definition of LFS [NCCN c6d08982].

Note that these claims and metrics are based solely on the provided context blocks and may not be a comprehensive summary of all available information on Li-Fraumeni Syndrome.

---

### q_synth_17: What are the modified requirements for inclusion of women with breast or ovarian cancer, considering their Ashkenazi Jewish descent?

**Expected ID:** `56698839` | **Hit@5:** 0 | **MRR:** 0.11

**Execution Path:** `route_recency ➔ retrieve ➔ grade_insufficient ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_fail ➔ generate ➔ validate_fail`

**Retrieved Sources:** PMID_29540360, f5ddd3f3, 4761845c, PMID_31074248, PMID_24131499, 4e9e4659, PMID_24737347, PMID_26687385, 56698839, PMID_22399190, e3cb4218, PMID_37535880, c2ee5568, f638eadd, 358c52b8, 102f77c1, 46492475, b28145a7, a8771cce, 696b1cfa, 54aeb8ec, 227a15bf, PMID_27294413

#### Generated Answer

> Based on the provided context, I can extract the following claims and metrics:

1. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer patients among Ashkenazi women [NCCN 4761845c].
2. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer: The prevalence was 12.8%, and the penetrance was 55% for BRCA1, while the prevalence was 4.6%, and the penetrance was 44% for BRCA2 [PubMed PMID_11179017].
3. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. The average risk of breast cancer was 65%, and the average risk of ovarian cancer was 39% [Am J Hum Genet 2003;72:1117-1130].
4. Risks of cancer in BRCA1-mutation carriers: A study found that women with BRCA1 mutations had a lifetime risk of developing breast cancer of approximately 65%, and a lifetime risk of developing ovarian cancer of approximately 39% [Lancet 1994;343:692-695].
5. The prevalence of BRCA1 mutations among young women with triple-negative breast cancer was found to be 14.3% [BMC Cancer 2009;9:86].
6. In a study comparing gynecological cancer risk management between women with BRCA variants of unknown significance (VUS) and women with negative genetic testing, there was no difference in the rate of risk-reducing bilateral salpingo-oophorectomy (RRBSO) [PubMed PMID_31074248].

As for Ashkenazi Jewish descent, I can extract the following claims:

1. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in about 60% of ovarian cancer patients among Ashkenazi women [NCCN 4761845c].
2. In a study on the experience of BRCA1/2 mutation-negative young women from hereditary breast and ovarian cancer (HBOC) families, all participants were of Ashkenazi Jewish descent [PubMed PMID_24131499].

Please let me know if you would like me to clarify any of these points or if there is anything else I can help with.

---

### q_synth_18: Should I perform molecular genetic testing for hereditary breast/ovarian cancer syndrome on a patient who has received an allogeneic bone marrow transplant?

**Expected ID:** `a87c3918` | **Hit@5:** 1 | **MRR:** 0.50

**Execution Path:** `route_conceptual ➔ retrieve ➔ grade_insufficient ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** 64b02c12, a87c3918, 881bcea8, e3cb4218, 36d26a7e, bbe9395f, ddfedb84, aaa254c6, 2c7f2e71, 78aee744, ddcbdf1c, 8c9e11cc, 27d184db, 2ab3e079, 6e56507d

#### Generated Answer

> Up to 10% of breast cancers are due to specific mutations in single genes that are passed down in a family [NCCN 64b02c12].

Specific patterns of hereditary breast/ovarian cancers are linked to mutations in the BRCA1 or BRCA2 genes [NCCN 64b02c12].

One or more of these criteria is suggestive of hereditary breast/ovarian cancer syndrome that warrants further personalized risk assessment, genetic counseling, and often genetic testing and management [NCCN a87c3918].

---

### q_synth_19: What are the guidelines for managing patients with cancer?

**Expected ID:** `dff7d8e5` | **Hit@5:** 0 | **MRR:** 0.00

**Execution Path:** `route_conceptual ➔ retrieve ➔ grade_insufficient ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_fail ➔ generate ➔ validate_fail`

**Retrieved Sources:** PMID_42416861, 397bd923, 3aa8ab22, dbbb8e61, 91a627de, 028c4de1, 92823412, PMID_42403667, 2aea525d, 67af1f9f, 8acd2f7d, 2bb97b2b, bf072a5a, 4c25fef6, NCT06995976, eb7b875b, ff8b4eab, PMID_42441083, 349ecd36, NCT06383871, PMID_42388532, NCT04125524, NCT04414150, PMID_42302807, PMID_42465713, PMID_42413527, PMID_42379203, NCT06926972

#### Generated Answer

> There is no specific claim or metric related to "cancer" in the provided context blocks. The abstract mentions esophagitis with marked eosinophilic infiltration, which requires differentiation from esophagogastric junction carcinoma, but it does not mention cancer as a whole. The references cited are mostly about genetic mutations and their association with various types of cancers, such as breast, ovarian, prostate, and gastric cancer.

---

### q_synth_20: What are some cancers associated with Li-Fraumeni Syndrome?

**Expected ID:** `e400f40f` | **Hit@5:** 0 | **MRR:** 0.00

**Execution Path:** `route_recency ➔ retrieve ➔ grade_insufficient ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** PMID_22672556, PMID_36290891, 8f94e72f, 4287e689, 359e9c3a, c2e7e563, 7d408bd4, 17d4523d, e560c787, dbc35d50, 3848f119, f42b2268, 3aa8ab22, 5955a477, PMID_33245408, 81d3e9e7, PMID_9173760, c6d08982, PMID_11027425, bf7df0a5

#### Generated Answer

> According to the provided context, here are some claims and metrics related to Li-Fraumeni Syndrome (LFS):

* LFS is an autosomal-dominant, inherited tumour predisposition syndrome associated with heterozygous germline mutations in the TP53 gene [PubMed PMID_22672556].
* Patients with LFS are at a high risk to develop early-onset breast cancer and multiple malignancies, among which sarcomas are the most common [PubMed PMID_22672556].
* A high incidence of childhood tumours and close to 100% penetrance has been described in patients with LFS [PubMed PMID_22672556].
* The lifetime risk of breast cancer has been estimated at about 1/10th of 1% (1 in 1,000) for individuals with LFS [NCCN 8f94e72f].
* Germline TP53 gene mutations have been estimated to be involved in only about 1% of hereditary breast cancer cases [NCCN 4287e689].
* The tumor suppressor gene, TP53, is located on chromosome 17 and the protein product of the TP53 gene (i.e., p53) is located in the cell nucleus and binds directly to DNA [NCCN 4287e689].
* Germline mutations in the TP53 gene have been found to be associated with a wide spectrum of early-onset cancers, including breast cancer, sarcomas, and adrenocortical carcinoma [NCCN 359e9c3a].

---

### q_synth_21: What is the percentage of breast cancer risk reduction in individuals with a BRCA2 mutation receiving tamoxifen compared to placebo?

**Expected ID:** `7478a0e2` | **Hit@5:** 0 | **MRR:** 0.12

**Execution Path:** `route_recency ➔ retrieve ➔ grade_failed ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** 833066f5, 85f737f6, b417bd05, d0b8b051, PMID_42032759, 696b1cfa, PMID_40358767, 7478a0e2, e3dc38b0, PMID_40705362, PMID_42433835, NCT00253539, 293034b0, ab6bd30a, 5a660ddc, NCT07499999, b8a2d9ff, PMID_41608012, c1ca28ff, 3404e0ab, ddd3d35c, a22210b3, PMID_41097794, NCT00381927

#### Generated Answer

> According to the provided context, it can be inferred that:

* Tamoxifen use was not associated with a reduction in breast cancer risk in those with a BRCA1 mutation [NCCN 833066f5]
* Oral contraceptives reduced the risk of ovarian cancer by 60% in BRCA2 mutation carriers [NCCN d0b8b051]
* Tamoxifen use was associated with a reduced risk of breast cancer among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial, with a risk ratio of 0.38 for BRCA2 mutation carriers receiving tamoxifen relative to placebo [NCCN b417bd05]

---

### q_synth_22: What is the recommendation for communicating reproductive risks to research participants identified through cancer panels, as per recent studies?

**Expected ID:** `78f2d39c` | **Hit@5:** 1 | **MRR:** 0.50

**Execution Path:** `route_recency ➔ retrieve ➔ grade_failed ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** NCT04579432, 78f2d39c, f543e8b3, c093a2dd, ddd3d35c, 542fbc74, 93d87b05, 0b93e94c, e1d9c157, 8ac9cf7c, NCT06346418, 8acd2f7d, 58406351, a6ae93d2, 82a0a6cf, 293034b0, PMID_42323841, PMID_42393826, PMID_42391314, PMID_42434969, 85dfc89e, PMID_42423388, PMID_42464117, PMID_42328968, NCT00438594, NCT00438282, NCT00443638, PMID_42351362

#### Generated Answer

> The World Health Organization (WHO) defines reproductive health as "not only the absence of disease or disability, but a state of complete physical, mental and social welfare in all matters related to the reproductive system, functions and processes" [NCCN].

Sexual and reproductive health and rights are essential for the health and survival of people, economic development and prosperity [NCCN].

---

### q_synth_23: What is the prevalence of germline mutations in cancer genes among pancreatic cancer patients with a positive family history?

**Expected ID:** `7983dd91` | **Hit@5:** 1 | **MRR:** 1.00

**Execution Path:** `route_recency ➔ retrieve ➔ grade_failed ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** 7983dd91, NCT02750657, 8b1caa1c, d4f4add9, a562d249, NCT05659914, NCT05138302, b8195f23, 9f806fa1, NCT03174574, af1e7129, PMID_42165335, PMID_42383254, PMID_42048949, NCT01188109, d6580360, 8dccefba, PMID_42288239, e7af7df2, PMID_42208634, 0a14d7c0, 657e7192, 7fa3c666, f31ad611, PMID_41742461, PMID_42322945, 6376b66a, PMID_41823133

#### Generated Answer

> According to the provided context, the following pancreatic cancer genes have been identified:

* BRCA1 [NCCN d4f4add9]
* BRCA2 [NCCN d4f4add9]
* PALB2 [NCCN d4f4add9]
* CDKN2A [NCCN 8b1caa1c]
* MAP2K4 [NCCN 8b1caa1c]
* MADH4 [NCCN 8b1caa1c]
* ACVR1B [NCCN 8b1caa1c]

These genes have been associated with germline mutations in pancreatic cancer patients, particularly those with a positive family history.

---

### q_synth_24: What chemoprevention options are available for breast cancer patients with BRCA mutations?

**Expected ID:** `293034b0` | **Hit@5:** 0 | **MRR:** 0.00

**Execution Path:** `route_recency ➔ retrieve ➔ grade_insufficient ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** cf59ea9b, 6f97e02a, a6fafd7b, ddfedb84, 4a846d8b, cd5a8e1e, PMID_42464142, 54aeb8ec, 34fd4821, e3cb4218, NCT06831747, a1132525, e41923b8, NCT01945775, e183ea3c, PMID_42467271, 8d4ac645, NCT02034916, PMID_42458138, NCT04038905, PMID_42224954, PMID_42292701, PMID_42025263, 7d408bd4, aaa254c6, NCT03351803, PMID_42259465, PMID_42155872

#### Generated Answer

> According to the provided context [NCCN cf59ea9b], BRCA1/BRCA2 mutation carriers have a higher breast cancer survival rate compared to non-carriers.

Source ID bracket: [NCCN cf59ea9b]

---

### q_synth_25: What is the mean age at diagnosis of ovarian cancer for BRCA1/2 carriers?

**Expected ID:** `5502812c` | **Hit@5:** 0 | **MRR:** 0.06

**Execution Path:** `route_recency ➔ retrieve ➔ grade_failed ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** 13a5a4ee, PMID_41875782, PMID_42462279, PMID_42458138, NCT03211611, PMID_42464142, NCT07197723, NCT04499534, 9038ce43, PMID_41693691, ed36b174, NCT03286842, db213d0b, 83d45c9a, 41962de5, 5502812c, PMID_42224954, db8c3721, 3b86bd00, 6f97e02a, 5a660ddc, 833066f5, a6fafd7b, e3cb4218, NCT04367675, e41923b8, PMID_41520277, PMID_42437126

#### Generated Answer

> Based on the provided context, here are some claims and metrics related to BRCA1/2:

* An individual with a known deleterious BRCA1/2 mutation in a close family member who does not undergo gene testing should be followed according to the same screening/management guidelines as a carrier of a BRCA1/2 mutation [NCCN 13a5a4ee].
* Rare germline BRCA1/2 variants were identified in 17 out of 367 patients (4.6%) with primary CNS tumors [PubMed PMID_42458138].
* Patients undergoing PGT-M, including BRCA carriers, experience greater cumulative IVF cycle burden, but the per cycle and per transfer probability of achieving a live birth is similar across indications [PubMed PMID_42462279].
* Pathogenic or likely pathogenic BRCA1/2 variants were identified in 5 out of 367 patients (1.4%) with primary CNS tumors [PubMed PMID_42458138].
* Variants of uncertain significance (VUSs) were identified in 12 out of 367 patients (3.3%) with primary CNS tumors [PubMed PMID_42458138].
* BRCA1/2 variants were identified in 158 out of 1,101 Vietnamese patients diagnosed with breast, ovarian, prostate, or pancreatic cancer (14.35%) [PubMed PMID_42464142].

Note that these claims and metrics are based on the provided context and may not be exhaustive or definitive for all scenarios related to BRCA1/2.

---

### q_synth_26: What is the prevalence of BRCA1 and BRCA2 founder mutations among Ashkenazi women with ovarian cancer or early-onset breast cancer?

**Expected ID:** `4761845c` | **Hit@5:** 0 | **MRR:** 0.17

**Execution Path:** `route_recency ➔ retrieve ➔ grade_insufficient ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** PMID_42235864, NCT00597987, a8771cce, PMID_42309254, e3cb4218, 4761845c, PMID_42329179, e41923b8, 85f737f6, a22210b3, NCT04499534, 2fa26ed8, db8c3721, 2aea525d, PMID_41467426, 833066f5, 225dce63, PMID_42026967, eceee09d, NCT04367675, e734bb10, 46492475, NCT03211611, PMID_42393830, PMID_41693691, NCT07197723, 914ccbf5, PMID_41520277

#### Generated Answer

> Here are the claims and metrics related to BRCA1 extracted from the provided context blocks:

* Lower expression of BRCA1 in cardiomyoblast alters the expression of apoptotic, inflammatory, and metabolic pathway genes, and enhances catecholamine-induced hypertrophic response [PubMed PMID_42235864].
* Knocking down BRCA1 altered apoptotic genes, and downregulated inflammatory and metabolic genes [PubMed PMID_42235864].
* Depletion of BRCA1 may result in remodeling of the heart, especially in the presence of stressful stimuli [PubMed PMID_42235864].
* High BARD1 expression correlates with poor prognosis in glioblastoma (GBM) [PubMed PMID_42309254].
* BARD1 undergoes liquid-liquid phase separation (LLPS) via its intrinsically disordered region (IDR, aa 113-425) [PubMed PMID_42309254].
* BRCA1 haploinsufficiency regulates gene expression on the X chromosome [ClinicalTrials.gov NCT00597987].
* The founder mutations 185delAG and 5382insC in BRCA1 appear in 60% of ovarian cancer patients among Ashkenazi women [NCCN 4761845c].
* Prevalence and penetrance of germline BRCA1 mutations in a population series of 649 women with ovarian cancer [NCCN 4761845c].
* Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history [Antoniou et al., 2003].

Let me know if you'd like me to clarify any of these claims or metrics!

---

### q_synth_27: What is the relationship between BRCA2 mutation carrier status and breast cancer risk?

**Expected ID:** `db213d0b` | **Hit@5:** 0 | **MRR:** 0.00

**Execution Path:** `route_recency ➔ retrieve ➔ grade_failed ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_fail ➔ generate ➔ validate_pass`

**Retrieved Sources:** 6f97e02a, 56f022e5, a6fafd7b, a8771cce, 3c31364f, 8b1caa1c, PMID_42464142, NCT07253051, ddfedb84, e41923b8, PMID_42446611, 962b95df, 5a660ddc, b417bd05, NCT04499534, a22210b3, e893376a, ee5207e2, PMID_42127212, PMID_41731704, NCT04613440, PMID_42446852, NCT03495609, aaa254c6, PMID_41823437, NCT04428736, PMID_42433303, PMID_42457876

#### Generated Answer

> According to the provided context blocks:

* BRCA2 mutations have been associated with a 2- to 5-fold increase in risk of prostate cancer [NCCN].
* Patients with BRCA2 mutations had more aggressive or rapidly progressive disease, and significantly decreased survival compared with patients who were BRCA1 mutation carriers or non-carriers [NCCN].
* BRCA2 mutation carriers with prostate cancer had a higher histologic grade [NCCN].

Please note that these claims are based on the provided context blocks and may not represent the entire scope of knowledge on this topic.

---

### q_synth_28: What are some studies that support the use of magnetic resonance imaging (MRI) for breast cancer screening in women with a hereditary risk of breast cancer?

**Expected ID:** `5ed1c261` | **Hit@5:** 0 | **MRR:** 0.00

**Execution Path:** `route_recency ➔ retrieve ➔ grade_insufficient ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** NCT05486520, PMID_42360310, 708f1902, NCT00639171, d4ab5493, NCT05989022, PMID_42119169, 0021dc41, 61d7a22a, 49920f89, PMID_42184602, 2f99c423, d61d06cb, 59b73b57, PMID_41934823, e3350e16, PMID_42361750, 373661ac, NCT02608281, 8d4ac645, 3c5e80bb, e4f55811, 89b57c77, 3285d012, NCT04340180, PMID_42441046, PMID_41725365, PMID_42082655

#### Generated Answer

> Based on the provided context, I found some relevant information about breast cancer MRI:

* A new method is being tested to image breast cancers at ultra-low magnetic field [ClinicalTrials.gov NCT05486520].
* The study aims to compare ultra-low field breast MRI with standard mammograms, ultrasounds, MRIs, clinical examinations, and pathology evaluations [ClinicalTrials.gov NCT05486520].
* A hybrid of 4 CNN-pertained networks (Res-Net18, Mobile-Net, Shuffle-Net, and Inception-V3) was applied on dynamic contrast-enhanced MRI examinations to assess the performance of AI in classifying breast images into normal, benign, and malignant [PubMed PMID_42360310].
* The Res-Net model achieved the highest accuracy, sensitivity, and specificity of 90.89%, 90.93%, and 95.39%, respectively, for MRI image classification [PubMed PMID_42360310].
* Magnetic resonance imaging (MRI) was used as one of the modalities in surveillance of women at high familial risk for breast cancer [NCCN 708f1902], [NCCN d4ab5493].

Please note that these findings are based on the provided context and may not be exhaustive or comprehensive.

---

### q_synth_29: What are some key references for understanding the roles of BRCA1 and BRCA2 in cancer?

**Expected ID:** `deb3e802` | **Hit@5:** 0 | **MRR:** 0.00

**Execution Path:** `route_recency ➔ retrieve ➔ grade_failed ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** PMID_42235864, NCT00597987, a8771cce, PMID_42309254, e3cb4218, 4761845c, PMID_42329179, e41923b8, 85f737f6, a22210b3, NCT04499534, 2fa26ed8, db8c3721, 2aea525d, PMID_41467426, 833066f5, 225dce63, PMID_42026967, eceee09d, NCT04367675, e734bb10, 46492475, NCT03211611, PMID_42393830, PMID_41693691, NCT07197723, 914ccbf5, PMID_41520277

#### Generated Answer

> Based on the provided context blocks, here are some claims and metrics related to BRCA1:

* Lower expression of BRCA1 in cardiomyoblast alters the expression of apoptotic, inflammatory and metabolic pathway genes, and enhances catecholamine-induced hypertrophic response [PubMed PMID_42235864]
* Successful knockdown of BRCA1 was achieved by developing lentiviral particles containing BRCA1 shRNA [PubMed PMID_42235864]
* High BARD1 expression correlates with poor prognosis in glioblastoma (GBM) [PubMed PMID_42309254]
* BRCA1 haploinsufficiency regulates gene expression on the X chromosome [ClinicalTrials.gov NCT00597987]
* Founder BRCA1 and BRCA2 mutations appear in 60% of ovarian cancer patients among Ashkenazi women [NCCN a8771cce]
* The prevalence of germline BRCA1 and BRCA2 mutations is approximately 40-50% in breast cancer cases among Ashkenazi women [NCCN 4761845c]
* Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations are estimated to be around 50-60% [Antoniou et al., 2003]

Note that these claims and metrics are based on the provided context blocks, which may not be an exhaustive list of all studies or findings related to BRCA1.

---

### q_synth_30: What is the term used to describe a graphic illustration of family history?

**Expected ID:** `5b861386` | **Hit@5:** 1 | **MRR:** 0.50

**Execution Path:** `route_conceptual ➔ retrieve ➔ grade_insufficient ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** 47e64f75, 5b861386, 8f5a60c5, f72aef68, 94203c0c, NCT00339508, 2dba6c49, NCT05710393, ea38a033, NCT01380925, PMID_42437051, NCT03222336, e8b87795, e400f40f, NCT00005139, PMID_42288229, 4b207490, fb696387, 43d652a2, PMID_42424135, PMID_41615819, PMID_42269807, PMID_41528256, PMID_41958050, 4746cc57, 397bd923, PMID_41676885, 7d4d0458

#### Generated Answer

> Here's the answer:

A graphic illustration of family history, usually referred to as a pedigree or family tree [NCCN 47e64f75]. 

A graphic illustration of family history, often referred to as a pedigree or family tree [NCCN 5b861386].

Pedigree: A graphic illustration of family history. Pedigree A [NCCN f72aef68].

The information is normally coded, and the researchers do not have access to the identification of the people whose information is in the files. Sometimes the content of the files gives rise to collaborations between the software developers and the providers of the files [ClinicalTrials.gov NCT00339508].

---

### q_synth_31: What is the estimated positive predictive value of Classic LFS criteria for detecting germline TP53 mutations?

**Expected ID:** `edea5eda` | **Hit@5:** 0 | **MRR:** 0.11

**Execution Path:** `route_recency ➔ retrieve ➔ grade_failed ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** PMID_40501034, PMID_42283722, PMID_40543052, cf8b4ff2, 344db784, PMID_42171906, 17941c35, 02626e7b, edea5eda, a45aff63, PMID_41922118, 38e0e4c0, c6d08982, PMID_41990740, d99fdc9f, 8f94e72f, 41fc8354, f42b2268, PMID_41129770, cca48bd4, 17d4523d, e560c787

#### Generated Answer

> Here's the answer:

Classic Li-Fraumeni Syndrome (LFS) criteria include [NCCN cf8b4ff2]:

* Member of a kindred with a known TP53 mutation
* Combination of an individual diagnosed at age 45 years or younger with a sarcoma, and:
	+ A first-degree relative diagnosed with cancer at age 45 years or younger
	+ An additional first- or second-degree relative in the same lineage with cancer diagnosed at age 45 years or younger, or a sarcoma at any age

[Source ID: NCCN cf8b4ff2]

Let me know if you have any further questions!

---

### q_synth_32: What is the recommended approach to genetic testing for an Ashkenazi Jewish individual with no known familial mutation?

**Expected ID:** `4e9e4659` | **Hit@5:** 1 | **MRR:** 0.25

**Execution Path:** `route_conceptual ➔ retrieve ➔ grade_insufficient ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** NCT00016471, NCT01102569, NCT00588263, 4e9e4659, NCT04668898, PMID_42337332, PMID_42334990, PMID_42456684, f5ddd3f3, 696b1cfa, 102f77c1, NCT00707694, PMID_41906789, b4ed6750, e3cb4218, b8195f23, f638eadd, 46492475, 56698839, PMID_42201816, 54aeb8ec, PMID_42439066, c2ee5568, a6fafd7b, PMID_42446297, 7e6908ae, bf7df0a5, PMID_42370242

#### Generated Answer

> Based on the provided context blocks, here are some claims and metrics related to the Ashkenazi Jewish population:

* The study aims to find the causes of all types of Usher syndrome in the Ashkenazi Jewish population [ClinicalTrials.gov NCT00016471].
* The participants will be taken from the Ashkenazi Jewish population group only to increase the power of the study and the likelihood of detecting relevant genes [ClinicalTrials.gov NCT00016471].
* The prevalence of BRCA1 c.68_69del variant is 3.6% in a community-based Roma sample with self-reported Ashkenazi Jewish ancestry [PubMed PMID_42337332].
* The mutation-age estimates were 925 years ago in non-Roma carriers and 600 years ago in Roma carriers, suggesting an Iberian founder later enriched in Roma with a high prevalence of BRCA1 c.68_69del in Spanish Roma and supporting targeted genetic screening within this community [PubMed PMID_42337332].

Note: These claims and metrics are specific to the Ashkenazi Jewish population, as mentioned in the context blocks.

---

### q_synth_33: What are the criteria for diagnosing Cowden syndrome?

**Expected ID:** `657e7192` | **Hit@5:** 0 | **MRR:** 0.00

**Execution Path:** `route_recency ➔ retrieve ➔ grade_insufficient ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** PMID_42394463, PMID_42397496, b8c62b1f, cf75e1c7, 458ba83e, NCT04094675, f6bba4cc, 940db7d7, 4c1f8474, PMID_42410002, 1190fbf3, NCT00971789, 2fe10e87, f12ef980, b0545db9, 5785cbf7, e637396b, 8bb5f2d3, e815c35b, 23ceeece, NCT00600275, PMID_42328350, PMID_42106060, PMID_42086021, NCT07218575, PMID_41966075, PMID_42350754, NCT06805734

#### Generated Answer

> Here are the extracted claims and metrics related to Cowden syndrome:

* Cowden syndrome is a hereditary cancer predisposition syndrome characterized by macrocephaly, mucocutaneous lesions, and increased cancer risk in the breast, thyroid, endometrium, kidneys, and colon [PubMed PMID_42394463].
* The incidence of Cowden syndrome has been reported to be 1 in 200,000, although it is likely to be underestimated due to difficulties associated with making a clinical diagnosis of the disease [NCCN b8c62b1c].
* Classic features of the disease include mucocutaneous papillomatous papules, palmoplantar keratoses, and trichilemmomas [NCCN 458ba83e].
* Most individuals with Cowden syndrome exhibit characteristic mucocutaneous lesions by their twenties, and such lesions have been reported to occur in 99% of individuals with Cowden syndrome [NCCN b8c62b1c].
* The presence of 2 or more trichilemmomas has been reported to be pathognomonic for Cowden syndrome [NCCN 458ba83e].

Note: These claims and metrics are based on the provided context blocks, which include abstracts, articles, and guidelines.

---

### q_synth_34: What is the approximate reduction in breast cancer risk achieved by bilateral risk reduction mastectomy in moderate- and high-risk women, as reported in studies with median follow-up periods of 13-14 years?

**Expected ID:** `92638e94` | **Hit@5:** 1 | **MRR:** 1.00

**Execution Path:** `route_recency ➔ retrieve ➔ grade_failed ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** 92638e94, dd9edc80, dd2d6ad4, c7827fba, 64c36ba7, 62ae6867, ee5207e2, PMID_42419307, e734bb10, NCT06239766, NCT04574063, de45be60, NCT06112977, PMID_42383458, PMID_41842879, eef3390a, 5502812c, 7e3672e3, 0ca27aa5, 125ecd85, 85dfc89e, NCT03346200, NCT04821141, PMID_41785110, PMID_41541191, PMID_42177995, PMID_42217484, PMID_42437126

#### Generated Answer

> Bilateral risk reduction mastectomy (RRM) decreased the risk of developing breast cancer by at least 90% in moderate- and high-risk women [NCCN 92638e94].

Breast cancer risk reduction was reported following Risk-reducing salpingo-oophorectomy (RRSO) in carriers of a BRCA1 and a BRCA2 mutation, respectively, with hazard ratios of 0.47 (95% CI, 0.29-0.77) [204] and 0.30 (95% CI, 0.11-0.84; P =0.022) [208].

A recent meta-analysis found similar reductions in breast cancer risk following RRSO, with an odds ratio of 0.44 (95% CI, 0.29-0.66; P <0.001) [210].

Risk-reducing salpingo-oophorectomy was associated with a 56% (odds ratio=0.44; 95% CI, 0.29-0.66; P <0.001) and a 43% (odds ratio=0.57; 95% CI, 0.28-1.15; P =0.11) breast cancer risk reduction in carriers of a BRCA1 and a BRCA2 mutation, respectively [210].

Breast cancer risk reduction by approximately 50% was reported following bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers [NCCN dd9edc80].

---

### q_synth_35: What is the association between hereditary diffuse gastric cancer and lobular breast cancer?

**Expected ID:** `1b4ff988` | **Hit@5:** 1 | **MRR:** 0.33

**Execution Path:** `route_recency ➔ retrieve ➔ grade_failed ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** NCT03950908, 7a58d5d0, 1b4ff988, NCT03648879, 92823412, 39f3d38d, 9583e206, NCT04253106, 5955a477, bbe9395f, NCT03030404, eb7b875b, 09690d4f, b28145a7, 9b636009, 3469e7f2, 3aa8ab22, PMID_42466845, PMID_42068022, aaa254c6, 7d408bd4, PMID_42226721, PMID_42021123, PMID_42163716, PMID_42262009, PMID_42107110, PMID_42253411, NCT00633607

#### Generated Answer

> According to the provided context blocks, here are some claims or metrics related to hereditary diffuse gastric cancer (HDGC):

* Germline mutation in e-cadherin gene (CDH1) is found in approximately 25% to 30% of individuals fulfilling the clinical criteria for HDGC [ClinicalTrials.gov NCT03950908]
* Prophylactic gastrectomy is the mainstay of the management of cases with pathogenetic CDH1 mutation, but some individuals refuse gastrectomy and prefer to delay it for medical or psychosocial reasons [ClinicalTrials.gov NCT03950908]
* HDGC is a rare hereditary syndrome that arises from mutation(s) in the CDH1 (cadherin 1, type 1, E-cadherin) gene which encodes for a tumor suppressor gene product [NCCN 7a58d5d0]
* People with hereditary gastric cancer syndrome are at increased risk of getting cancer in their stomach [ClinicalTrials.gov NCT03648879]
* HDGC is associated with development of lobular breast cancer [NCCN 1b4ff988]
* The incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families is reported to be approximately 1348-1353 [Pharoah et al. Gastroenterology 2001;121:1348-1353, NCCN 92823412]

Note that these claims or metrics are extracted from the provided context blocks and may not represent the only relevant information available on hereditary diffuse gastric cancer.

---

### q_synth_36: What are the inherited p53 gene mutations in breast cancer, and what are their clinical characteristics?

**Expected ID:** `e57a4c7d` | **Hit@5:** 0 | **MRR:** 0.06

**Execution Path:** `route_recency ➔ retrieve ➔ grade_insufficient ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** ee926745, NCT03381781, PMID_42163716, PMID_42297232, NCT03377725, 4eddeff9, 91a627de, 3aa8ab22, 7d408bd4, 4287e689, NCT06088030, ff8b4eab, dbc35d50, PMID_42320297, 17309b28, e57a4c7d, 17d4523d, e560c787, ed960604, f42b2268, PMID_42361739, c368ec89, PMID_42376199, NCT05631886, PMID_42241743, NCT07419893, PMID_42078583, PMID_41593906

#### Generated Answer

> According to the provided context blocks:

* TP53 mutation is commonly associated with poor cancer patient prognosis [PubMed PMID_42163716]
* p53 mutation is associated with extremely poor prognosis in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) patients [ClinicalTrials.gov NCT03381781]
* TP53 mutation is a risk factor for a wide spectrum of early-onset cancers [NCCN 4eddeff9]
* The TP53 mutational spectrum and frequency of CHEK2*1100delC in Li-Fraumeni-like kindreds are characterized by a specific pattern of mutations [Siddiqui R, Onel K, Facio F, et al. Fam Cancer 2005;4:177-181]
* Risks of first and subsequent cancers among TP53 mutation carriers are increased compared to the general population [Mai PL, Best AF, Peters JA, et al. Cancer 2016;122:3673-3681]

---

### q_synth_37: What are the studies that evaluated breast cancer screening using magnetic resonance imaging (MRI) and mammography for women at high familial risk of breast cancer?

**Expected ID:** `24ba9149` | **Hit@5:** 0 | **MRR:** 0.09

**Execution Path:** `route_trials ➔ retrieve ➔ grade_failed ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** NCT06843083, PMID_42360310, d4ab5493, df07e7df, 708f1902, PMID_42401077, 49920f89, NCT01869335, 95bfd1f1, 373661ac, 24ba9149, 8d4ac645, NCT02608281, NCT04832191, PMID_42081023, PMID_42419307, e3350e16, PMID_41437877, c246905d, 61d7a22a, 3c5e80bb, 382d6c7d, PMID_42469044, 3285d012, PMID_41935244, f81b01d4, PMID_42224832, NCT03684733

#### Generated Answer

> Here are some claims and metrics extracted from the provided context blocks:

* Res-Net model achieved the highest accuracy (90.89%), sensitivity (90.93%), and specificity (95.39%) for classifying breast images into normal, benign, and malignant [PubMed PMID_42360310].
* Mobile-net network recorded the highest accuracy (88.55%), sensitivity (88.49%), and specificity (94.22%) for classifying MRI image classification [PubMed PMID_42360310].
* ResNet-18 showed the most optimal model for extracting features from mammograms compared with other CNN networks (Mobile-Net, Shuffle-Net, and Inception-V3) while Mobile-Net model was the most suitable in MRI [PubMed PMID_42360310].
* The AUC ranged between 0.95 and 0.97 among pretrained networks for mammography image classification and was higher (0.99) for the hybrid model [PubMed PMID_42360310].
* The AUC ranged between 0.94 and 0.96 among pretrained networks for MRI image classification and was higher (0.98) for the Hybrid model [PubMed PMID_42360310].

Note that these are just some of the claims and metrics extracted from the provided context blocks, and there may be additional information relevant to breast cancer MRI mammography in other parts of the text.

---

### q_synth_38: What is the effect of hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers?

**Expected ID:** `e734bb10` | **Hit@5:** 0 | **MRR:** 0.00

**Execution Path:** `route_recency ➔ retrieve ➔ grade_failed ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_fail ➔ generate ➔ validate_pass`

**Retrieved Sources:** NCT03777852, 028c4de1, 7e3672e3, PMID_42393830, 31f38fd9, 2596d6fb, PMID_42319344, 1789db19, PMID_42377119, 81f94efb, NCT05408676, bf072a5a, PMID_42390481, 92823412, 85dfc89e, PMID_42421228, d4ab5493, dbbb8e61, PMID_42371677, 85f737f6, 11fe09cf, e36481d3, 44ca3e3d, NCT01110954, NCT05781633, PMID_42337391, NCT01522300, PMID_42329179

#### Generated Answer

> Breast cancer is the most common type of cancer among women worldwide [ClinicalTrials.gov NCT03777852].

Breast cancer is a feared disease in the female universe because it is considered one of the major causes of death due to neoplasia among women [ClinicalTrials.gov NCT03777852].

In Brazil, breast cancer is second only to non-melanoma skin cancer [ClinicalTrials.gov NCT03777852].

---

### q_synth_39: What is the estimated lifetime risk of developing breast cancer for carriers of ATM mutations?

**Expected ID:** `7f417d6e` | **Hit@5:** 1 | **MRR:** 0.20

**Execution Path:** `route_recency ➔ retrieve ➔ grade_failed ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** 2a7cdb18, NCT05010031, NCT06177171, 7fa3c666, 7f417d6e, d8e21f2e, f31ad611, NCT03009682, cd5a8e1e, 2e1a113a, PMID_42092301, 9f806fa1, 14f6ceef, 6376b66a, PMID_42419313, 1a7b121c, f86ed189, PMID_42092629, f59bf018, 92fcd241, PMID_42172983, 9af48c8e, PMID_42401126, PMID_42155956, PMID_42119969, PMID_42176651, NCT05694715, NCT03962114

#### Generated Answer

> Here are the claims and metrics related to ATM mutations extracted from the provided context:

* About 1% of patients with breast cancer have an ATM mutation [NCCN d8e21f2e]
* ATM mutation carriers have a 38% lifetime risk of developing breast cancer [NCCN d8e21f2e]
* Carriers of the c.7271T>G missense mutation have a 69% risk of developing breast cancer by 70 years of age [NCCN d8e21f2e]
* The c.7271T>G variant is associated with an increased risk for breast cancer (OR, 11.60; 95% CI, 1.50-89.90; P = .001) [NCCN d8e21f2e]
* The c.7271T>G variant is also associated with an increased risk for breast cancer in families with pathogenic ATM variants (HR, 8.0; 95% CI, 2.3-27.4; P < .001) [NCCN d8e21f2e]
* An estimated RR of 2.8 (90% CI, 2.2-3.7; P < .001) is associated with ATM-heterozygous germline mutations and breast cancer-susceptibility [NCCN 7f417d6e]

Please note that these claims and metrics are based solely on the provided context blocks and do not represent any broader or more comprehensive information about ATM mutations.

---

### q_synth_40: What is the distinction between sporadic cancer and cancer that occurs in people who carry a germline pathogenic or likely pathogenic variant?

**Expected ID:** `dc805963` | **Hit@5:** 0 | **MRR:** 0.11

**Execution Path:** `route_recency ➔ retrieve ➔ grade_insufficient ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** PMID_41954240, PMID_42377349, NCT03296826, a562d249, PMID_41621779, PMID_42269807, NCT03982446, PMID_42386664, dc805963, PMID_42288229, 7e6908ae, 5b861386, c89916bc, NCT07204392, PMID_42377220, a0f46dfb, 4287e689, f42b2268, PMID_41903835, NCT07556562, 7983dd91, a6fafd7b, 7fa3c666, 6e56507d, 34a6a9d1, 225dce63, 38396210, NCT07019155

#### Generated Answer

> Here are the answers based on the provided context:

* Germline genetic variations were investigated in Chinese neuroendocrine tumor (NET) patients, and 11.5% of cases carried germline pathogenic or likely pathogenic variants [PubMed PMID_41954240].
* The study found that MEN1 was the most frequently mutated gene, accounting for 3.5% of all enrolled patients, followed by PALB2, SDHB, and BRIP1 [PubMed PMID_41954240].
* Germline variants of ATP1A1 caused hypomagnesemia with treatment-resistant seizures [PubMed PMID_42377349].
* The study identified a germline mutation in the MLH1 gene that disrupts DNA mismatch repair and is detectable by digital PCR [PubMed PMID_42269807].
* Pathogenic germline variants were detected in 10,389 adult cancers [NCCN a562d249].

---

### q_synth_41: What is the 10-year survival rate among PALB2 carriers with breast cancer?

**Expected ID:** `e0d03fa1` | **Hit@5:** 0 | **MRR:** 0.05

**Execution Path:** `route_recency ➔ retrieve ➔ grade_failed ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** 8e667a47, NCT06403904, NCT04756765, 6a189b4f, e893376a, NCT06783140, a0fcd36b, NCT06078787, PMID_42431822, 07099419, PMID_41954240, NCT05232006, PMID_42127212, PMID_42358519, 1789db19, 92fcd241, 9af48c8e, e183ea3c, e0d03fa1, PMID_42238311, 80b6a6e3, 2e1a113a, 1a7b121c, PMID_41823437, 6376b66a, aeb93ff2, PMID_42426004, PMID_42036279

#### Generated Answer

> Here are the claims and metrics related to PALB2 extracted from the provided context blocks:

* PALB2 pathogenic or likely pathogenic variants are associated with increased risk for breast cancer [NCCN 8e667a47]
* The estimated risk ratio (RR) of developing breast cancer is 5.3 (90% CI, 3.0-9.4) in individuals with PALB2 mutations [NCCN 8e667a47]
* Among 1494 BC patients analyzed by MGP test, 33 were PALB2 mutation carriers (2%) [ClinicalTrials.gov NCT06403904]
* Women with no family history of breast cancer have a cumulative risk of 33% compared to 58% in women with two or more family members with breast cancer who carry a PALB2 mutation [NCCN 8e667a47]
* The estimated frequency of PALB2 mutations is approximately 0.6% to 3% among patients with breast cancer [NCCN 8e667a47]

These are the relevant claims and metrics related to PALB2 extracted from the provided context blocks.

---

### q_synth_42: What is the frequency of BRCA1 and BRCA2 mutations in male breast cancer cases from a population-based study?

**Expected ID:** `1789db19` | **Hit@5:** 0 | **MRR:** 0.00

**Execution Path:** `route_recency ➔ retrieve ➔ grade_failed ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** PMID_42235864, NCT00597987, a8771cce, PMID_42309254, e3cb4218, 4761845c, PMID_42329179, e41923b8, 85f737f6, a22210b3, NCT04499534, 2fa26ed8, db8c3721, 2aea525d, PMID_41467426, 833066f5, 225dce63, PMID_42026967, eceee09d, NCT04367675, e734bb10, 46492475, NCT03211611, PMID_42393830, PMID_41693691, NCT07197723, 914ccbf5, PMID_41520277

#### Generated Answer

> According to the provided context, here are some claims and metrics related to BRCA1:

* Lower expression of BRCA1 in cardiomyoblast alters the expression of apoptotic, inflammatory and metabolic pathway genes, and enhances catecholamine-induced hypertrophic response [PubMed PMID_42235864].
* The founder mutations 185delAG and 5382insC in BRCA1 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women [NCCN 4761845c] [Abeliovich et al., Am J Hum Genet 1997;60:505-514].
* Average risks of breast and ovarian cancer associated with BRCA1 mutations detected in case series unselected for family history: a combined analysis of 22 studies [Antoniou et al., Am J Hum Genet 2003;72:1117-1130].
* Risks of cancer in BRCA1-mutation carriers [Ford et al., Lancet 1994;343:692-695].
* Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2 [King et al., Science 2003;302:643-646].

These findings suggest that BRCA1 is associated with an increased risk of breast and ovarian cancers, particularly among Ashkenazi Jewish women.

---

### q_synth_43: What is the frequency of BRCA mutations in Ashkenazi Jewish men with prostate cancer?

**Expected ID:** `54aeb8ec` | **Hit@5:** 0 | **MRR:** 0.00

**Execution Path:** `route_recency ➔ retrieve ➔ grade_failed ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** NCT03838406, a6fafd7b, 4a846d8b, cf59ea9b, NCT02034916, NCT02222883, e3cb4218, 5a660ddc, NCT06831747, 3404e0ab, 373661ac, 285852e3, 2fa26ed8, dbbb8e61, 767a1cf8, NCT01945775, b8a2d9ff, 3f8ded64, 8d4ac645, 914ccbf5

#### Generated Answer

> Based on the provided context, here are some claims and metrics related to BRCA:

* Germline BRCA mutations denote a clinicopathologic subset of prostate cancer [NCCN a6fafd7b].
* BRCA2 mutations denote a clinicopathologic subset of prostate cancer in Ashkenazi Jews [NCCN a6fafd7b].
* The effect of a single BRCA2 mutation on cancer in Iceland was studied [NCCN 4a846d8b].
* Cancer risks in BRCA2 families: estimates for women with breast and ovarian cancers were provided [NCCN 4a846d8b].
* Germline BRCA1/2 mutation testing is indicated [NCCN cf59ea9b].
* Breast cancer survival of BRCA1/BRCA2 mutation carriers in a hospital-based cohort of young women was evaluated [NCCN cf59ea9b].
* Earlier age of onset of BRCA mutation-related cancers in subsequent generations was observed [NCCN cf59ea9b].

Please note that these are just some of the claims and metrics related to BRCA, and there may be more information available in the provided context.

---

### q_synth_44: What is recommended for individuals who do not meet criteria for testing but are still considered at increased risk of familial breast cancer?

**Expected ID:** `148bdffc` | **Hit@5:** 0 | **MRR:** 0.08

**Execution Path:** `route_conceptual ➔ retrieve ➔ grade_insufficient ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** NCT04058418, e893376a, PMID_42068564, 1b0de65c, PMID_42223121, d644bf93, ff8b4eab, PMID_42297814, 67af1f9f, 2596d6fb, 81f94efb, 148bdffc, 3ed0b25d, 17d4523d, 4c25fef6, PMID_42252839, 6cc1e1b5, PMID_42033881, 7d408bd4, 397bd923, PMID_41991965, PMID_41846317, NCT03959267, 6e56507d, NCT05392608, NCT02557776, NCT03495544, PMID_41321007

#### Generated Answer

> Based on the provided context, I can extract the following claims and metrics:

1. Chemoprevention medication may lower the risk of developing breast cancer by a third [PubMed PMID_42068564].
2. The prevalence rate of CHEK2 pathogenic or likely pathogenic variant is about 1% in large samples of patients with breast cancer [NCCN d644bf93].
3. The cumulative lifetime risk for breast cancer in women with CHEK2 mutations and familial breast cancer ranges from approximately 28% to 37% [NCCN d644bf93].
4. The estimated RR (relative risk) for breast cancer, based on data from two large case-control studies, was 3.0 (90% CI, 2.6-3.5) [NCCN d644bf93].

Please note that these claims and metrics are extracted from the provided context blocks and may not be exhaustive or representative of all relevant information related to familial breast cancer.

---

### q_synth_45: What are some examples of studies that used preimplantation genetic diagnosis for BRCA1/2 mutations?

**Expected ID:** `17309b28` | **Hit@5:** 0 | **MRR:** 0.00

**Execution Path:** `route_recency ➔ retrieve ➔ grade_failed ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** 13a5a4ee, PMID_41875782, PMID_42462279, PMID_42458138, NCT03211611, PMID_42464142, NCT07197723, NCT04499534, 9038ce43, PMID_41693691, ed36b174, NCT03286842, db213d0b, 83d45c9a, 41962de5, 5502812c, PMID_42224954, db8c3721, 3b86bd00, 6f97e02a, 5a660ddc, 833066f5, a6fafd7b, e3cb4218, NCT04367675, e41923b8, PMID_41520277, PMID_42437126

#### Generated Answer

> Based on the provided context, here are some claims and metrics related to BRCA1/2:

* An individual with a known deleterious BRCA1/2 mutation in a close family member who does not undergo gene testing should be followed according to the same screening/management guidelines as a carrier of a BRCA1/2 mutation [NCCN 13a5a4ee]
* Rare germline BRCA1/2 variants were identified in 17 of 367 patients (4.6%) with primary CNS tumors [PubMed PMID_42458138]
* Among the 17 patients with rare germline BRCA1/2 variants, 5 patients (1.4% of the overall cohort) carried pathogenic or likely pathogenic variants, whereas 12 patients (3.3%) carried variants of uncertain significance (VUSs) [PubMed PMID_42458138]
* Patients undergoing PGT-M, including BRCA carriers, experience greater cumulative IVF cycle burden. However, the per cycle and per transfer probability of achieving a live birth was similar across indications, supporting reassuring counseling for BRCA carriers pursing IVF/PGT-M [PubMed PMID_42462279]
* Pathogenic BRCA1 variants were identified in 57/158 ovarian cancers, and pathogenic BRCA2 variants were identified in 17/158 ovarian cancers [PubMed PMID_42464142]
* The mutation burden was highest in ovarian cancer and TNBC, where BRCA1 variants predominated over BRCA2 (40/57 BRCA1 vs 17/57 BRCA2 in ovarian cancer and 57/78 BRCA1 vs 21/78 BRCA2 in TNBC) [PubMed PMID_42464142]
* Several BRCA1 truncating variants (c.4997dup, c.5251C > T, c.5335del) and recurrent BRCA2 loss-of-function variants were enriched in triple-negative breast cancer (TNBC), with additional cases observed in ovarian, prostate, and pancreatic cancers [PubMed PMID_42464142]
* Knowledge scores regarding BRCA1/2 genetic testing increased significantly from 6.87 ± 2.95 at baseline to 12.74 ± 3.42 post-intervention (p < 0.001) [PubMed PMID_41875782]
* Attitude scores similarly improved from 5.40 ± 2.04-9.67 ± 2.44 (p < 0.001) [PubMed PMID_41875782]

Please note that these claims and metrics are extracted from the provided context blocks, and you must append the exact Source ID bracket to the end of each sentence, as shown in the example.

---

### q_synth_46: What is the recommended approach for genetic counseling when a patient has cancer and a family history of diffuse gastric cancer?

**Expected ID:** `9b636009` | **Hit@5:** 0 | **MRR:** 0.06

**Execution Path:** `route_conceptual ➔ retrieve ➔ grade_insufficient ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** 3aa8ab22, 7d408bd4, PMID_42311607, 1b4ff988, 92823412, bbe9395f, 39f3d38d, PMID_42068022, 9583e206, b28145a7, NCT00320515, 3469e7f2, eb7b875b, e7af7df2, PMID_42021123, 9b636009, PMID_42058264, NCT03890354, PMID_42311610, NCT02661945, PMID_42318089, NCT03208777, 227a15bf, PMID_42247321, aaa254c6, NCT01579071, 028c4de1, PMID_41709439

#### Generated Answer

> Gastric cancer in individuals with Li-Fraumeni syndrome was reported to occur [Genet Med 2011;13:651-657].

---

### q_synth_47: What reproductive options should patients of reproductive age be advised on, considering pre-implantation genetic diagnosis?

**Expected ID:** `58406351` | **Hit@5:** 0 | **MRR:** 0.07

**Execution Path:** `route_conceptual ➔ retrieve ➔ grade_insufficient ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** NCT00173732, NCT02502214, 17309b28, 2a472db3, NCT02149485, e290fc72, f9d4c96b, NCT01336400, 0b93e94c, 30f6e1ae, 3e217395, a8eaf819, 3f8ded64, 82a0a6cf, 58406351, PMID_42462758, NCT04474522, 7d511538, fdf8330e, PMID_41785458, PMID_42267492, PMID_42268245, PMID_42469189, PMID_41761862, PMID_42325582, bf7df0a5, 373b0df6

#### Generated Answer

> Preimplantation Genetic Diagnosis (PGD) is the integration of both assisted reproductive technologies and molecular genetic technologies [ClinicalTrials.gov NCT00173732].

PGD for monogenic diseases is usually performed by multiplex PCR combining polymorphic microsatellites familial analysis and, where possible, couple-specific mutation detection [ClinicalTrials.gov NCT02502214].

A targeted next-generation sequencing approach has been proposed for the PGD for cystic fibrosis, which would allow a PGD for probably almost every couple asking for it in our centre, without a previous couple-specific development [ClinicalTrials.gov NCT02502214].

Preimplantation genetic diagnosis (PGD) has been performed in The Netherlands since 1995 for couples at high risk for transmitting severe or lethal genetic conditions or who have experienced multiple miscarriages due to chromosomal translocations [ClinicalTrials.gov NCT02149485].

Multiple displacement amplification (MDA) is a technique used in the amplification of very low amounts of DNA and reported to yield large quantities of high-quality DNA, which can be applied to PGD [ClinicalTrials.gov NCT00173732].

PGD has been shown to improve implantation rate and reduce spontaneous abortions after implantation [ClinicalTrials.gov NCT00173732].

The principal problems in single cell PCR include amplification failure, ADO and contamination [ClinicalTrials.gov NCT00173732].

---

### q_synth_48: What percentage of males with breast cancer who were not selected based on family history test positive for a germline BRCA2 mutation?

**Expected ID:** `f0a40c19` | **Hit@5:** 0 | **MRR:** 0.00

**Execution Path:** `route_trials ➔ retrieve ➔ grade_failed ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** 6f97e02a, 56f022e5, a6fafd7b, a8771cce, 3c31364f, 8b1caa1c, PMID_42464142, NCT07253051, ddfedb84, e41923b8, PMID_42446611, 962b95df, 5a660ddc, b417bd05, NCT04499534, a22210b3, e893376a, ee5207e2, PMID_42127212, PMID_41731704, NCT04613440, PMID_42446852, NCT03495609, aaa254c6, PMID_41823437, NCT04428736, PMID_42433303, PMID_42457876

#### Generated Answer

> Here are the claims and metrics related to BRCA2 mutations:

* BRCA2 mutations have been associated with a 2- to 5-fold increase in risk of prostate cancer [NCCN 6f97e02a].
* BRCA2 mutations denote a clinicopathologic subset of prostate cancer, characterized by more aggressive or rapidly progressive disease and decreased survival compared with patients who were BRCA1 mutation carriers or non-carriers [NCCN a6fafd7b].
* Patients with BRCA2 mutations had more aggressive or rapidly progressive prostate cancer, and significantly decreased survival compared with patients who were BRCA1 mutation carriers or non-carriers [NCCN a6fafd7b].
* BRCA2 mutation carriers with prostate cancer had more aggressive or rapidly progressive disease, and significantly decreased survival compared with patients who were BRCA1 mutation carriers or non-carriers [NCCN a6fafd7b].

---

### q_synth_49: What changes were made to the genetic testing recommendation for family members without known familial mutations of PTEN?

**Expected ID:** `6d3ab963` | **Hit@5:** 0 | **MRR:** 0.00

**Execution Path:** `route_recency ➔ retrieve ➔ grade_failed ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** NCT03680924, NCT02991807, NCT05630105, dff55cce, c4880433, 69c1e674, f12ef980, e815c35b, NCT06080165, NCT05111080, d7d63e25, 27b7c02e, c79217ce, bddeb8e2, PMID_41527390, e096f867, bdc5189f, 39f3d38d, 57186224, PMID_41817392, 704948de, PMID_42359636, PMID_41953055, e637396b, PMID_42009253, PMID_41730753, PMID_42199066, PMID_42035472

#### Generated Answer

> Based on the provided context, here are some claims and metrics related to PTEN:

* The PTEN gene located on chromosome 10 encodes for a tumor suppressor protein involved in cell cycle control and cell survival [NCCN dff55cce]
* Phosphatase and TENsin homolog (PTEN) gene germline mutations are associated with a spectrum of clinical manifestations characterized by neurocognitive deficits, intellectual disability, autism symptomatology, skin lesions, macrocephaly, hamartomatous overgrowth of tissues, and an increased risk of cancers [ClinicalTrials.gov NCT02991807]
* Inactivation of PTEN and dysregulation of the phosphoinositol-3-kinase/Akt pathway cause human Lhermitte-Duclos disease in adults [NCCN 69c1e674]
* Germline PTEN tumor suppressor gene mutations are associated with a subset of individuals with autism spectrum disorders and extreme macrocephaly [NCCN c4880433]

Note that these claims are not specific metrics, but rather statements about the relationship between PTEN and certain diseases or conditions. If you're looking for specific metrics related to PTEN, I'd be happy to help if more information is provided.

---

### q_synth_50: When should premenopausal women perform breast self-exam training for optimal awareness?

**Expected ID:** `df3c1b7b` | **Hit@5:** 0 | **MRR:** 0.12

**Execution Path:** `route_recency ➔ retrieve ➔ grade_failed ➔ augment ➔ retrieve ➔ grade_insufficient ➔ generate ➔ validate_pass`

**Retrieved Sources:** NCT07562321, PMID_40078357, NCT06777745, NCT07692464, NCT05418985, PMID_38320959, 32101cad, df3c1b7b, 93d87b05, PMID_42002553, e7a138c0, 0ca27aa5, 59b73b57, f81b01d4, PMID_41563932, e3f0b71f, 382d6c7d, PMID_40254639, c093a2dd, PMID_41952563, f348e333, PMID_39949918, NCT05995483, 0bca2262, e3350e16, bf072a5a, 11fe09cf

#### Generated Answer

> Breast self-exam (BSE) training is a crucial aspect of early breast cancer detection and treatment.

[ClinicalTrials.gov NCT07562321] Trial Title: IMPACT OF AN AI-SUPPORTED FLIPPED LEARNING MODEL ON NURSING STUDENTS' BREAST SELF-EXAMINATION KNOWLEDGE AND PERFORMANCE: A RANDOMIZED CONTROLLED TRIAL. Status: RECRUITING.
Objective: This study aims to evaluate the effect of AI-supported flipped learning model and traditional education on the knowledge levels and performance skills of nursing students regarding BSE knowledge and skills.

[ClinicalTrials.gov NCT06777745] Trial Title: Improvement of Breast Examination Skills of Midwifery Students: Model Supported Education Study. Status: NOT_YET_RECRUITING.
Summary: Practical training of midwifery students helps them to ensure the effectiveness and correct application of BSE.

[ClinicalTrials.gov NCT07692464] Trial Title: The Effect of Breast Self-Examination Education Using Visual Materials on Breast Cancer Awareness and Health Motivation Among Illiterate Women of Reproductive Age: A Study in Diyarbakır, Türkiye. Status: ACTIVE_NOT_RECRUITING.
Summary: The educational content will include breast anatomy, signs and symptoms of breast cancer, the importance of early detection, and the correct steps for performing BSE.

[ClinicalTrials.gov NCT05418985] Trial Title: The Effect of Monthly Text Message Reminder After Training on Beliefs and Practice Behaviors Regarding Women's Breast Self Examination: Randomized Controlled Study. Status: COMPLETED.
Summary: This study was conducted to examine the effect of monthly telephone message reminders after training on women's beliefs and practice behaviors regarding BSE.

[PubMed PMID_38320959] Title: Effect of monthly reminders by telephone message on women's beliefs and practice behaviours regarding breast self-examination: A randomized controlled study..

As per these sources, breast self-exam (BSE) training is essential for early detection and treatment of breast cancer. The studies highlight the importance of practical training for midwifery students and the role of visual materials in improving breast cancer awareness among illiterate women.

---

